Addex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
Addex Therapeutics Ltd., a foreign private issuer headquartered in Geneva, Switzerland, filed this Form 6-K on April 25, 2025. The filing serves to distribute a press release dated April 25, 2025, and the company's Annual Report for 2024. The registrant files annual reports under Form 20-F.
Key Financial Metrics
The provided filing text acts as a cover document and does not contain specific financial data points. Consequently, values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this excerpt. These metrics are contained within the attached Annual Report 2024 (Exhibit 99.1), which is incorporated by reference but not detailed in the text provided.
Material Changes
The filing text does not disclose specific material changes versus prior periods. It references the inclusion of the 2024 Annual Report and a new press release, but the content of these documents regarding financial or operational changes is not summarized in the filing text itself.
Guidance, Outlook, and Risks
Management commentary, future guidance, specific risks, contingencies, or unusual items are not described in the provided text. The filing indicates that a press release was issued on the filing date, but its specific content regarding outlook or risks is not included in the source text.
Investor Verification Checklist
- Review Exhibit 99.1 (Annual Report 2024) for audited financial statements and detailed operational results.
- Read Exhibit 99.2 (Press Release dated April 25, 2025) for the specific announcement triggering this filing.
- Verify the incorporation of these exhibits into the company's active registration statements (Form F-3 No. 333-255089 and Form S-8 Nos. 333-255124 and 333-272515).
- Confirm the company's continued status as a foreign private issuer filing under Form 20-F.